製品番号: HY-11006

KU-57788

(別名: NU7441)

44 Cited Publications

カスタマーレビュー

Based on 44 publication(s) in Google Scholar

KU-57788 (NU7441) is a highly potent and selective DNA-PK inhibitor with an IC₅₀ of 14 nM. KU-57788 is an NHEJ pathway inhibitor. KU-57788 also inhibits PI3K and mTOR with IC₅₀s of 5.0 and 1.7 μM, respectively.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.95%
CAS 番号: 503468-95-9
分子式: C₂₅H₁₉NO₃S
分子量:413.49

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

KU-57788 構造式

CAS 番号: 503468-95-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
化学情報
Publications (44)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

DNA-PK

14 nM (IC₅₀)

mTOR

1.7 μM (IC₅₀)

PI3K

5.0 μM (IC₅₀)

CRISPR/Cas9

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	14 μM Compound: 2, NU7441	Inhibition of human ERG expressed in cisapride treated CHO cells by Ion Works assay Inhibition of human ERG expressed in cisapride treated CHO cells by Ion Works assay	[PMID: 23855836]
Cortical neurone	EC₅₀	1.2 μM Compound: NU7441	Neuroprotective activity in rat cortical neurons transfected with an mHTT-exon1-Q73 construct in presence of primary corticostriatal co-culture system assessed as rescue from mHTT-induced survival loss by fluorescent reporter based assay Neuroprotective activity in rat cortical neurons transfected with an mHTT-exon1-Q73 construct in presence of primary corticostriatal co-culture system assessed as rescue from mHTT-induced survival loss by fluorescent reporter based assay	[PMID: 30840447]
HeLa	EC₅₀	212 nM Compound: 2, NU7441	Inhibition of DNA-PK autophosphorylation at S2056 in human HeLa cells Inhibition of DNA-PK autophosphorylation at S2056 in human HeLa cells	[PMID: 23855836]
HeLa	IC₅₀	14 nM Compound: Chemical Probe: NU7441	Inhibition of human HeLa cell nuclear extract purified DNA-PK using p53 peptide as substrate by ELISA Inhibition of human HeLa cell nuclear extract purified DNA-PK using p53 peptide as substrate by ELISA	[PMID: 16707462]
LoVo	GI₅₀	0.52 μM Compound: Chemical Probe: NU7441	Growth inhibition of human LoVo cells measured after 5 days by crystal violet staining based assay Growth inhibition of human LoVo cells measured after 5 days by crystal violet staining based assay	[PMID: 16707462]

体外実験

NU7441 (0.5 to 10 μM) inhibits the growth of liver cancer HepG2 cells dose- and time-dependently. NU7441 reduces pDNA-PKcs (S2056) protein expression in liver cancer cells. Furthermore, double treatment of NU7441 and 60Coγ IR affects DNA damage repair^[2].
NU7441 is solvent-exposed in BRD4, this inhibitor can be classified as a Type I BRD inhibitor^[4].
NU7441 reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 503468-95-9
性状 Solid
分子量 413.49
分子式 C₂₅H₁₉NO₃S
Color White to off-white
SMILES

O=C1C=C(N2CCOCC2)OC3=C1C=CC=C3C4=CC=CC5=C4SC6=C5C=CC=C6
別名

NU7441
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (44)

All Flow CytometryBio/Physico-chemical AssayCell Imaging/StainingIn Vivo ImagingIHCCell Proliferation/Viability AssayIP

Sort by:

Journal Impact Factor

Cell

Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]

2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601
Nat Biotechnol

High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition. [Abstract]

2024 May;42(5):731-744. PMID: 37537500
Cell Metab

Innate immune response orchestrates phosphoribosyl pyrophosphate synthetases to support DNA repair. [Abstract]

2021 Oct 5;33(10):2076-2089.e9. PMID: 34343500

KU-57788 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2021 Oct 5;33(10):2076-2089.e9. [Abstract]

FHs 74 Int cells with expression of FLAG-TBK1 were pretreated with NU7441 (1 μM), KU55933 (10 μM),or AZD6738 (2μM) for 2h, and then exposed to 10 Gy ionizing radiation. Immunoprecipitation analyses with anti-FLAG M2 agarose beads were performed 30 min after irradiation.
Adv Mater

A Nucleophilicity-Engineered DNA Ligation Blockade Nanoradiosensitizer Induces Irreversible DNA Damage to Overcome Cancer Radioresistance. [Abstract]

2024 Sep 9:e2410031. PMID: 39246208
Nat Methods

Exonuclease-enhanced prime editors. [Abstract]

2024 Mar;21(3):455-464. PMID: 38302659
Nat Cell Biol

Full-length GSDME mediates pyroptosis independent from cleavage. [Abstract]

2024 Sep;26(9):1545-1557. PMID: 38997456
Cancer Res

Inhibition of mTOR Enhances the Efficacy of Proteasome-Dependent Targeted Protein Degradation Approaches. [Abstract]

2026 Jan 13. PMID: 41529091
Nat Commun

Refined DNA repair manipulation enables a universal knock-in strategy in mouse embryos. [Abstract]

2025 Jul 15;16(1):6502. PMID: 40664653
Nat Commun

A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer. [Abstract]

2025 Jan 27;16(1):1077. PMID: 39870664
J Clin Invest

DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. [Abstract]

2024 Oct 22:e180278. PMID: 39436696

KU-57788 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 22:e180278. [Abstract]

The tumor cell line was treated with DMSO or DNA-PKi (2 μM NU7441) for 48 hours, at which point the drug was washed off prior to coculturing with TILs at a 1:1 ratio for 18 hours. Cytotoxicity was determined by annexin V staining with flow cytometric gating on tumor cells (based on light scatter and CD3^–) and viability dye.

KU-57788 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 22:e180278. [Abstract]

B16-F10 melanoma cells were treated with 2 μM NU7441 or DMSO control for 72 hours, at which point gradual darkening was observed.
J Exp Clin Cancer Res

Flap endonuclease 1 and DNA-PKcs synergistically participate in stabilizing replication fork to encounter replication stress in glioma cells. [Abstract]

2022 Apr 12;41(1):140. PMID: 35414100
Adv Sci (Weinh)

TRIM24 Cooperates with Ras Mutation to Drive Glioma Progression through snoRNA Recruitment of PHAX and DNA-PKcs. [Abstract]

2024 Jun 3:e2400023. PMID: 38828688

KU-57788 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun 3:e2400023. [Abstract]

NU7441 (0-2 μM; 24 h). Morphological changes of NHA/HRasV12/TRIM24 cells treated with NU7441 for 24 h at indicated concentrations.

KU-57788 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun 3:e2400023. [Abstract]

NU7441 (20 mg/kg; ip). Representative bioluminescent (BLI) images of treated animals on day 10.

KU-57788 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun 3:e2400023. [Abstract]

NU7441 (20 mg/kg; ip). Representative images showing H&E and IHC staining of brain cross sections of NHA/HRas^V12/TRIM24‐derived tumors from animals treated with NU7441 or vehicle for 7 days.

KU-57788 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun 3:e2400023. [Abstract]

NU7441 (0.01-100 μM; 48 h). Viability of NHA/HRas^V12 cells with or without ectopic expression of TRIM24 at 48 h after treatment with NU7441.
Cell Death Dis

Inhibition of miR-1193 leads to synthetic lethality in glioblastoma multiforme cells deficient of DNA-PKcs. [Abstract]

2020 Jul 30;11(7):602. PMID: 32732911
Cancer Lett

GPI inactivation mediates pentose phosphate pathway flux switch-on inducing temozolomide resistance in glioma stem cell. [Abstract]

2026 May 1:645:218384. PMID: 41763452
Cancer Lett

N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer. [Abstract]

2023 Apr 1:558:216092. PMID: 36806557
Genome Biol

Effective control of large deletions after double-strand breaks by homology-directed repair and dsODN insertion. [Abstract]

2021 Aug 20;22(1):236. PMID: 34416913
Cell Rep

53BP1 regulates p53-E2F7-dependent transcriptional gene repression and participates in the Fanconi anemia pathway. [Abstract]

2025 Aug 12;44(8):116152. PMID: 40811062
Cell Rep

The N-degron pathway mediates the autophagic degradation of cytosolic mitochondrial DNA during sterile innate immune responses. [Abstract]

2024 Dec 21;44(1):115094. PMID: 39709605
Cell Rep

Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. [Abstract]

2023 Oct 16;42(10):113256. PMID: 37847590
PLoS Biol

DNA damage induced by HIV-1 Vpr triggers epigenetic remodeling and transcriptional programs to enhance virus transcription and latency reactivation. [Abstract]

2026 Feb 2;24(2):e3003621. PMID: 41628238
PLoS Biol

Loss of the abasic site sensor HMCES is synthetic lethal with the activity of the APOBEC3A cytosine deaminase in cancer cells. [Abstract]

2021 Mar 31;19(3):e3001176. PMID: 33788831
Genome Res

Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs. [Abstract]

2021 Mar;31(3):461-471. PMID: 33574136
J Cell Biol

Non-catalytic allostery in α-TAT1 by a phospho-switch drives dynamic microtubule acetylation. [Abstract]

2022 Nov 7;221(11):e202202100. PMID: 36222836
J Cell Biol

DNA damage promotes microtubule dynamics through a DNA-PK-AKT axis for enhanced repair. [Abstract]

2021 Feb 1;220(2):e201911025. PMID: 33404607
Radiother Oncol

DNA-dependent protein kinase regulates cytosolic double-stranded DNA secretion from irradiated macrophages to increase radiosensitivity of tumors. [Abstract]

2024 Apr:193:110111. PMID: 38286241
Cancer Biol Ther

Epigenetic silencing L3MBTL4 sensitizes esophageal cancer to DNA-PKcs inhibitor. [Abstract]

2026 Dec 31;27(1):2646393. PMID: 41876459
Int J Mol Sci

CRISPR/Cas9 Ribonucleoprotein Delivery Enhanced by Lipo-Xenopeptide Carriers and Homology-Directed Repair Modulators: Insights from Reporter Cell Lines. [Abstract]

2025 May 3;26(9):4361. PMID: 40362595
Int J Mol Sci

Chloroquine-Induced DNA Damage Synergizes with Nonhomologous End Joining Inhibition to Cause Ovarian Cancer Cell Cytotoxicity. [Abstract]

2022 Jul 7;23(14):7518. PMID: 35886866
Molecules

In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. [Abstract]

2020 Apr 23;25(8):1980. PMID: 32340370
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Neoplasia

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. [Abstract]

2018 Mar 28;20(5):478-488. PMID: 29605721
Cell Signal

MYC amplification sensitizes TNBC to CHK1 inhibitors. [Abstract]

2025 Jul:131:111709. PMID: 40037423
J Cereb Blood Flow Metab

Activin A alleviates neuronal injury through inhibiting cGAS-STING-mediated autophagy in mice with ischemic stroke. [Abstract]

2023 May;43(5):736-748. PMID: 36537048
Mol Carcinog

Pyroptosis-related gene GSDMC indicates poor prognosis and promotes tumor progression by activating the AKT/mTOR pathway in lung squamous cell carcinoma. [Abstract]

2024 Nov;63(11):2218-2236. PMID: 39136610
Mol Biol Rep

p53-deficient cancer cells hyperactivate DNA double-strand break repair pathways to overcome chemotherapeutic damage and augment survival. [Abstract]

2025 Mar 22;52(1):333. PMID: 40119972
Vet Microbiol

Porcine IGFBP3 promotes porcine circovirus type 2 replication via PERK/eIF2α mediated DNA damage. [Abstract]

2023 Dec:287:109897. PMID: 37922860
Mutat Res Genet Toxicol Environ Mutagen

Analysis of chromatid-break-repair detects a homologous recombination to non-homologous end-joining switch with increasing load of DNA double-strand breaks. [Abstract]

2021 Jul;867:503372. PMID: 34266628
Radiat Res

Nucleoside Analogs Radiosensitize G0 Cells by Activating DNA End Resection and Alternative End-Joining. [Abstract]

2021 May 1;195(5):412-426. PMID: 33755161
State University of New York at Stony Brook

2026.
bioRxiv

Oxidative DNA lesions destabilize centromeres and drive chromosome instability. [Abstract]

2026 May 1:2026.04.28.717272. PMID: 42094395
Patent

US20250288582A1.
bioRxiv

2023 Dec 19.
University of Gothenburg

2023 Jun 27.
University of Duisburg-Essen

2020 Jul.

溶剤 & 溶解度

体外:

DMSO : 6.67 mg/mL (16.13 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4184 mL

12.0922 mL

24.1844 mL

5 mM

0.4837 mL

2.4184 mL

4.8369 mL

10 mM

0.2418 mL

1.2092 mL

2.4184 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.67 mg/mL (1.62 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.67 mg/mL (1.62 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.67 mg/mL (1.62 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[2]

HepG2 cells (4000 per well) are cultured in a 96-well plate for 24 h. Once the cells complete the attachment, 0.1 µM, 1 µM, 5 µM, and 10 µM of KU-57788 are added to the culture media. After 12 h of KU-57788 treatment, 10% CCK-8 solution is added into the culture media, and the incubation continued for two h. OD450 values are determined by a spectrometer, and the results are analyzed to measure the cell growth.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (290 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Justin J J Leahy, et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6083-7. [Content Brief]

[2]. Yang C, et al. NU7441 Enhances the Radiosensitivity of Liver Cancer Cells. Cell Physiol Biochem. 2016;38(5):1897-905 [Content Brief]

[3]. Hardcastle IR, et al. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46 [Content Brief]

[4]. Ember SW, et al. The acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem Biol. 2014 Feb 25. [Content Brief]

[5]. Robert F, et al. Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. Genome Med. 2015 Aug 27;7:93 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4184 mL	12.0922 mL	24.1844 mL	60.4610 mL
	5 mM	0.4837 mL	2.4184 mL	4.8369 mL	12.0922 mL
	10 mM	0.2418 mL	1.2092 mL	2.4184 mL	6.0461 mL
	15 mM	0.1612 mL	0.8061 mL	1.6123 mL	4.0307 mL

Keywords

KU-57788

44 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

KU-57788

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

MedChemExpress（MCE）の使用を引用している文献 KU-57788

生物活性

化学情報

Publications (44)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

KU-57788

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

MedChemExpress（MCE）の使用を引用している文献 KU-57788

生物活性

化学情報

Publications (44)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

KU-57788 関連分類

HY-11006 関連分類